# A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis

> **NCT03334396** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 660 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Baricitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03334396
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-23
- **Primary completion:** 2018-12-06
- **Final completion:** 2019-08-16
- **Target enrollment:** 660 (ACTUAL)
- **Last updated:** 2020-08-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03334396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03334396, "A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03334396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*